You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

405 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Pegaspargase - Extranodal Natural Killer/T-cell Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
methotrexate,
leucovorin,
ifosfamide,
mesna,
dexamethasone,
etoposide,
pegaspargase
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2023
Document
Dec 2021
Document
Dec 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    entrectinib - For the treatment of locally advanced (not amenable to curative therapy) or metastatic NSCLC, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
entrectinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2024
Guidelines and Advice
Status: Current
ID: PET 2021-1
Jan 2022
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
sotorasib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2022
Guidelines and Advice
Status: Current
Version: 1
Feb 2022
Guidelines and Advice
Status: Current
ID: PET 2021-2
Jun 2022
Drug
Other Name(s): Rozlytrek®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2024
Document
Aug 2022
Document
Aug 2022
Document
Aug 2022

Pages